Compare Albemarle Corp. (ALB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Vertex Pharmaceuticals Incorporated — how do they compare? Albemarle Corp. trades at $130.2 (market cap $15.48B), while Vertex Pharmaceuticals Incorporated trades at $528.01 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.6× Albemarle Corp.'s market cap, and Albemarle Corp. pays a 1.25% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ALB | VRTX | |
|---|---|---|
Market Cap | $15.48B | $132.79B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $529.65 |
52-Week Low | $72.58 | $376.62 |
Enterprise Value | $17.96B | $126.92B |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $131.11, up 4.54% today, with a bullish technical signal and strong Q2 2026 earnings beating estimates. The stock shows improved cash flow and lithium demand strength, though valuation metrics like a P/E of 485.59 indicate high expectations. Recent news highlights earnings growth and dividend stability, with support at $127 and resistance at $134.
Outlook is cautiously optimistic with analyst consensus target of $184.50, but risks include volatile lithium prices and high valuation. Investment opportunity lies in sustained demand for energy storage, balanced by margin pressures and debt levels.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
